ADORA1 and ovarian carcinoma: Notably, treatment with the ADORA1 antagonist SLV320 partially rescued the adenosine-mediated decrease in A2780 cell survival, suggesting that ADORA1 may play a tumor-suppressive role in ovarian cancer [36].